A 6-year-old boy from a slum in Delhi presents with his mother complaining of eye discharge and mild redness for 2 weeks. On examination, he has follicles on the upper tarsal conjunctiva and mild conjunctival inflammation. Giemsa staining of conjunctival scrapings shows intracytoplasmic inclusion bodies. His mother reports that two younger siblings also have similar symptoms. What is the most appropriate immediate management?

Explanation

## Clinical Diagnosis This child has **active trachoma (TF stage)** — characterized by: - Follicular conjunctivitis (follicles on upper tarsal conjunctiva) - Mild conjunctival inflammation - Intracytoplasmic inclusions on Giemsa stain (pathognomonic for *Chlamydia trachomatis*) - Age < 10 years in an endemic area (Delhi slum) - Household transmission (two siblings also affected) ## Why Oral Azithromycin + Mass Treatment (Option B) is Correct **High-Yield:** The WHO SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) recommends **oral azithromycin** as the first-line antibiotic for active trachoma in children, especially in endemic settings with household spread. **Key Point:** Oral azithromycin 20 mg/kg as a single dose (or 12 mg/kg/day × 3 days) is the **gold standard** for active trachoma because: 1. **Superior efficacy** — achieves higher conjunctival tissue levels than topical therapy 2. **Short regimen** — 3-day course dramatically improves compliance vs. 6-week topical therapy 3. **Systemic reach** — eliminates *Chlamydia trachomatis* from nasopharyngeal and other reservoirs, preventing reinfection 4. **Enables mass drug administration (MDA)** — practical and effective in endemic communities 5. **Treats household contacts simultaneously** — critical when siblings are symptomatic ## Why the Other Options Are Suboptimal | Option | Reason Incorrect | |--------|-----------------| | **A) Topical tetracycline 1% QID × 6 weeks** | Effective but inferior to oral azithromycin in endemic settings; poor compliance with 6-week regimen; does NOT treat systemic/nasopharyngeal reservoir; does NOT address household contacts — inadequate when siblings are affected | | **C) Conjunctival biopsy** | Completely unnecessary; Giemsa stain showing intracytoplasmic inclusions is already diagnostic of *C. trachomatis*; biopsy adds no value and delays treatment | | **D) Systemic doxycycline** | **Contraindicated in children < 8 years** due to permanent tooth discoloration and enamel hypoplasia (KD Tripathi, Essentials of Medical Pharmacology); this 6-year-old cannot receive doxycycline | ## Contact Tracing & Mass Treatment **Clinical Pearl:** Trachoma spreads rapidly in households and schools via eye-seeking flies, shared towels, and direct contact. With two siblings already symptomatic, mass treatment of all household contacts is mandatory. In endemic communities, WHO recommends MDA when trachoma prevalence exceeds 10% in children aged 1–9 years. ## Dosing Reference - **Oral azithromycin:** 20 mg/kg single dose (max 1 g) OR 12 mg/kg/day × 3 days - **Alternative** (if oral not feasible): Topical tetracycline 1% ointment QID × 6 weeks ## Follow-up - Clinical reassessment at 3–6 months - If follicles persist, repeat treatment course - Monitor for progression to cicatricial stage (trichiasis, entropion) **Reference:** WHO Guidelines for the Management of Trachoma; Park's Textbook of Preventive and Social Medicine (SAFE strategy); KD Tripathi, Essentials of Medical Pharmacology (doxycycline contraindication in children)